濟川藥業(600566.SH):濟川有限的蒲地藍消炎口服液、蛋白琥珀酸鐵口服溶液將退出省級醫保目錄
格隆匯6月28日丨濟川藥業(600566.SH)公佈,此前披露,公司全資子公司濟川藥業集團有限公司(簡稱“濟川有限”)的品種蒲地藍消炎口服液、蛋白琥珀酸鐵口服溶液等未納入國家醫保目錄,已納入部分省級醫保目錄,隨着各省配套政策的執行、地方醫保目錄的調整,公司上述產品將於2022年12月31日前逐步調整出醫保支付範圍。
根據江蘇省、湖南省、吉林省、天津市、青海省省級單位醫保結算體系的相關要求,蒲地藍消炎口服液將於2022年6月30日起調出省級醫保目錄,其中,江蘇省、湖南省、吉林省、青海省醫保基金對調出藥品的結算支付至2022年12月31日。
根據江蘇省、湖南省省級單位醫保結算體系的相關要求,蛋白琥珀酸鐵口服溶液將於2022年6月30日起調出省級醫保目錄,江蘇省、湖南省醫保基金對調出藥品的結算支付至2022年12月31日。
2021年度,蒲地藍消炎口服液在江蘇省、湖南省、吉林省、青海省、天津市的銷售金額約7億元。蛋白琥珀酸鐵口服溶液在江蘇省、湖南省的銷售金額約1億元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.